Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study.
Ito A, Kim SW, Matsuoka KI, Kawakita T, Tanaka T, Inamoto Y, Toubai T, Fujiwara SI, Fukaya M, Kondo T, Sugita J, Nara M, Katsuoka Y, Imai Y, Nakazawa H, Kawashima I, Sakai R, Ishii A, Onizuka M, Takemura T, Terakura S, Iida H, Nakamae M, Higuchi K, Tamura S, Yoshioka S, Togitani K, Kawano N, Suzuki R, Suzumiya J, Izutsu K, Teshima T, Fukuda T.
Ito A, et al. Among authors: kawakita t.
Int J Hematol. 2020 Nov;112(5):674-689. doi: 10.1007/s12185-020-02960-4. Epub 2020 Aug 3.
Int J Hematol. 2020.
PMID: 32748216